RANBAXY DELIVERS STRONG OVERALL BASE BUSINESS PERFORMANCE AND IMPROVEMENT IN EBITDA MARGINS

Printer-friendly versionPDF version

The Board of Directors of Ranbaxy Laboratories Limited (RLL, NSE: RANBAXY, BSE: 500359), at their meeting held today, took on record the unaudited results for the Quarter ended September 30, 2011 (the “Q3’11”) under Indian GAAP.

Key Financial Highlights

Financial Performance for the quarter ended September 30, 2011 (Q3’11)

Financial Performance for the nine months ended September 30, 2011 (FY YTD Sep’11)

Commenting on the business results for the quarter, Mr. Arun Sawhney, CEO & Managing Director, Ranbaxy, said, “Ranbaxy’s focus on long term improvement of its base business and margins has begun to reflect in the Company’s performance. This is resulting from an increased focus on strengthening manufacturing processes while re-aligning our products and markets for value creation.”

Key Highlights/Developments

Business

Regulatory, Research & Development

Global Sales

Consolidated sales for the Quarter were $443 Mn (Rs. 20,280 Mn) as compared to $404 Mn (Rs. 18,809 Mn) in the corresponding quarter, of the previous year. Emerging markets contributed $262 Mn, accounting for ~60% of total sales. Developed markets recorded $145 Mn of sales and contributed 33% to total sales for the Company. API and others accounted for the rest of the revenue for the Quarter.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company’s commitment to increase penetration and improve access to medicines, across the globe. For more information, please visitwww.ranbaxy.com.

News Source : RANBAXY DELIVERS STRONG OVERALL BASE BUSINESS PERFORMANCE AND IMPROVEMENT IN EBITDA MARGINS